Quadrature Capital’s Grace Therapeutics GRCE Stock Holding History

Quadrature Capital’s Portfolio GRCE Stock Details GRCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-66,822	Closed	-$309K	–	2150
2026 Q1	$309K	Buy	+66,822	New	+$262K	﹤0.01%	969

Other funds holding GRCE

Cerity Partners New York $82.7B AUM 28.53% 1-Year Est. Return

Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Maven Securities St Helier, Jersey $5.06B AUM 59.27% 1-Year Est. Return

Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return

Cantor Fitzgerald New York $9.31B AUM 73.66% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Quadrature Capital's GRCE Position: Q2 2026 in Review

Quadrature Capital sold out of Grace Therapeutics (GRCE) in Q2 2026, closing a stake of 66,822 shares — an estimated $309K sold.

Quadrature Capital first reported a position in GRCE in Q1 2026 and held it in 1 quarter. The position peaked at $309K in Q1 2026. 33 funds tracked by Wall St. Rank hold GRCE as of Q2 2026.

Quadrature Capital reported no remaining Grace Therapeutics position as of Q2 2026 after selling out during the quarter.
Quadrature Capital sold 66,822 Grace Therapeutics shares in Q2 2026, an estimated $309K.
Quadrature Capital first reported a position in Grace Therapeutics in Q1 2026 and held it in 1 quarter.
Quadrature Capital's Grace Therapeutics position peaked at $309K in Q1 2026.
33 funds tracked by Wall St. Rank held Grace Therapeutics as of Q2 2026.

Based on Quadrature Capital's 13F filing for Q2 2026, filed 7 Aug 2026.